摘要
在肝细胞肝癌(HCC)治疗中,评估肿瘤对肝细胞肝癌治疗的反应是迅速确定后续治疗和后续策略的关键。按照传统,疗效标准一直是基于肿瘤大小的变化;然而,自从免疫治疗和靶向治疗在肝细胞肝癌的治疗中取得突破性的进展,并且,免疫治疗和靶向治疗会对肿瘤微环境中血管生成及血流产生影响。因此,肿瘤的血管在超声造影(CEUS)增强模式的变化被认为是更可靠的。超声造影及定量分析软件可以进行微血管灌注研究,是早期肿瘤反应评估的比较有效的工具。本文对目前有关CEUS在监测肝细胞肝癌靶向和免疫治疗反应中的作用的文献进行了综述。
In hepatocellular carcinoma(HCC)therapy,assessment of tumor response to HCC therapy is critical to rapidly identify subsequent therapies and subsequent strategies.According to tradition,response criteria have always been based on changes in tumor size;however,since immunotherapy and targeted therapy have made breakthrough advances in the treatment of hepatocellular carcinoma,and,due to the relationship between angiogenesis and immune regulation in the tumor microenvironment,changes in the enhancement pattern of tumor vessels in contrast-enhanced ultrasound(CEUS)are considered to be more reliable contrast-enhanced ultrasound and quantitative analysis software can perform microvascular perfusion studies and are relatively effective tools for early tumor response assessment.In this paper,we review the current literature on the role of CEUS in monitoring the response to targeted and immunotherapy for hepatocellular carcinoma.
作者
刘磊
沈廷允
刘玉鑫
戴维
LIU Lei;SHEN Tingyun;LIU Yuxin;DAI Wei(Department of Hepatobiliary and Pancreatic Surgery,Affiliated Hospital of Guangdong Medical University,Guangdong Province,Zhanjiang 524000,China)
出处
《中国当代医药》
CAS
2023年第23期33-36,共4页
China Modern Medicine
关键词
肝细胞肝癌
靶向治疗
免疫治疗
超声造影
Hepatocellular carcinoma
Contrast-enhanced ultrasound
Targeted therapy
Immunotherapy
